GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD

This study has been completed.

First Received: October 17, 2007 No Changes Posted

Sponsor:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00546624

Purpose

This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Condition	Intervention	Phase
Anxiety Disorder	Drug: MK0777	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Resource links provided by NLM:

MedlinePlus related topics: Anxiety

U.S. FDA Resources

Further study details as provided by Merck:

Study Start Date:	November 2002
Study Completion Date:	December 2003

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Have been diagnosed with Generalized Anxiety Disorder
Women of childbearing potential must use a double-barrier methods of contraception and must have a negative blood pregnancy test at the beginning of the study

Exclusion Criteria:

History of drug or alcohol abuse
Have previously participated in another study using MK0777

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00546624

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

Study ID Numbers:	2007_632
Study First Received:	October 17, 2007
Last Updated:	October 17, 2007
ClinicalTrials.gov Identifier:	NCT00546624 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Anxiety Disorders
Mental Disorders

ClinicalTrials.gov processed this record on February 04, 2010